Patel, Sandip Pravin

PD-L1 expression as a predictive biomarker in cancer immunotherapy

Patel, S. P., & Kurzrock, R. (2015) · Molecular Cancer Therapeutics

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 2,291

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

Goodman, A. M., Kato, S., Bazhenova, L., Patel, S. P., Frampton, G. M., Miller, V., Stephens, P. J., Daniels, G. A., & Kurzrock, R. (2017) · Molecular Cancer Therapeutics

Cancer Immunotherapy and BiomarkersCancer Genomics and Diagnostics

Cited by 2,264

RETRACTED ARTICLE: Microbiome analyses of blood and tissues suggest cancer diagnostic approach

Poore, G. D., Kopylova, E., Zhu, Q., Carpenter, C., Fraraccio, S., Wandro, S., Kosciolek, T., Janssen, S., Metcalf, J., Song, S. J., et al. (2020) · Nature

Cancer Genomics and DiagnosticsGut microbiota and health

Cited by 989

NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021: Featured Updates to the NCCN Guidelines

Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., D’Amico, T. A., et al. (2021) · Journal of the National Comprehensive Cancer Network

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 948

Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology

Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., Budde, L. E., Costa, L., Davies, M., Dunnington, D., et al. (2019) · Journal of the National Comprehensive Cancer Network

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 570

Pan-cancer analyses reveal cancer-type-specific fungal ecologies and bacteriome interactions

Narunsky-Haziza, L., Sepich-Poore, G. D., Livyatan, I., Asraf, O., Martino, C., Nejman, D., Gavert, N., Stajich, J. E., Amit, G., González, A., et al. (2022) · Cell

Gut microbiota and healthFungal Infections and Studies

Cited by 538

Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

Negrao, M. V., Araujo, H. A., Lamberti, G., Cooper, A. J., Akhave, N. S., Zhou, T., Delasos, L., Hicks, J. K., Aldea, M., Minuti, G., et al. (2023) · Cancer Discovery

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 203

Safety and efficacy of COVID‐19 vaccines: A systematic review and meta‐analysis of controlled and randomized clinical trials

Beladiya, J., Kumar, A., Vasava, Y., Parmar, K., Patel, D., Patel, S., Dholakia, S., Sheth, D., Boddu, S. H. S., & Patel, C. (2024) · Reviews in Medical Virology

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 96

Path toward Precision Oncology: Review of Targeted Therapy Studies and Tools to Aid in Defining “Actionability” of a Molecular Lesion and Patient Management Support

Chae, Y. K., Pan, A. P., Davis, A. A., Patel, S. P., Carneiro, B. A., Kurzrock, R., & Giles, F. J. (2017) · Molecular Cancer Therapeutics

Cancer Genomics and DiagnosticsLung Cancer Treatments and Mutations

Cited by 70

Phase Ib Study of Crizotinib plus Pembrolizumab in Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer with ALK Translocation

Patel, S. P., Pakkala, S., Pennell, N. A., Reckamp, K. L., Lanzalone, S., Polli, A., Tarazi, J., & Robert-Vizcarrondo, F. (2020) · The Oncologist

Lung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers

Cited by 34

Incidence of Thyroid Function Test Abnormalities in Patients Receiving Immune-Checkpoint Inhibitors for Cancer Treatment

Patel, N. S., Oury, A., Daniels, G. A., Bazhenova, L., & Patel, S. P. (2018) · The Oncologist

Cancer Immunotherapy and BiomarkersThyroid Disorders and Treatments

Cited by 25